Rozanolixizumab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 89 publications
Nipocalimab (Imaavy) for myasthenia gravis.
Journal: The Medical letter on drugs and therapeutics
Published: May 15, 2026
Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis.
Journal: Neurology and therapy
Published: February 25, 2026
Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: February 17, 2026
Combined inhibition of complement C5 and neonatal Fc receptor in refractory generalized myasthenia gravis: A report of two cases.
Journal: Journal of neuroimmunology
Published: February 07, 2026
Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.
Journal: American journal of therapeutics
Published: January 08, 2026
Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis.
Journal: Journal of neurology
Published: January 06, 2026
Body weight distribution of US patients with myasthenia gravis.
Journal: Journal of medical economics
Published: December 21, 2025
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.
Journal: Advances in therapy
Published: December 16, 2025
Depletion and recovery of IgG following treatment with Rozanoliximab and Imlifidase in pigtail macaques.
Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025
Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: A disproportionality analysis based on the FAERS database.
Journal: Human vaccines & immunotherapeutics
Published: November 13, 2025
Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: November 10, 2025
Rozanolixizumab as rescue therapy in triple-seronegative refractory generalized myasthenia gravis.
Journal: Immunological medicine
Published: November 10, 2025
Last Updated: 06/30/2026